Sustained low‐dose agonist CD40 monoclonal antibody delivered via NDES effectively triggers anti‐tumor immune response in immunosuppressive pancreatic tumor microenvironment without treatment‐related adverse events. The gene discussed is CD40; the disease is neoplasm.